• Publications
  • Influence
Remission in schizophrenia: proposed criteria and rationale for consensus.
New advances in the understanding of schizophrenia etiology, course, and treatment have increased interest on the part of patients, families, advocates, and professionals in the development ofExpand
  • 1,581
  • 188
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest,Expand
  • 2,805
  • 104
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.
OBJECTIVE Neuropsychological impairments are well documented in schizophrenia and are important targets of treatment. Information about the severity and pattern of deficits after treatment for theExpand
  • 858
  • 45
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
CONTEXT Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychoticExpand
  • 762
  • 41
What does the PANSS mean?
OBJECTIVE Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms of schizophrenia, the clinical meaning of its total score and of the cut-offs that areExpand
  • 799
  • 37
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
OBJECTIVE The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. METHOD In a 12-week,Expand
  • 401
  • 29
The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). II: Multi-site test-retest reliability study
A test-retest reliability study of the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II) was conducted on 284 subjects in four psychiatric patient sites and twoExpand
  • 353
  • 27
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
BACKGROUND Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. The present study investigated the efficacy, safety, and tolerability ofExpand
  • 520
  • 25
Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder.
In recent years, lower serum levels have been recommended for maintenance therapy with lithium. We studied 94 patients with bipolar disorder in a randomized, double-blind, prospective trial of twoExpand
  • 312
  • 25
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia
Evolutionarily significant selective sweeps may result in long stretches of homozygous polymorphisms in individuals from outbred populations. We developed whole-genome homozygosity association (WGHA)Expand
  • 278
  • 25